Type 1 diabetes mellitus

A Katsarou, S Gudbjörnsdottir, A Rawshani… - Nature reviews Disease …, 2017 - nature.com
Type 1 diabetes mellitus (T1DM), also known as autoimmune diabetes, is a chronic disease
characterized by insulin deficiency due to pancreatic β-cell loss and leads to …

Harnessing the plasticity of CD4+ T cells to treat immune-mediated disease

M DuPage, JA Bluestone - Nature Reviews Immunology, 2016 - nature.com
CD4+ T cells differentiate and acquire distinct functions to combat specific pathogens but
can also adapt their functions in response to changing circumstances. Although this …

[HTML][HTML] The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes

S Dong, KJ Hiam-Galvez, CT Mowery, KC Herold… - JCI insight, 2021 - ncbi.nlm.nih.gov
BACKGROUND A previous phase I study showed that the infusion of autologous Tregs
expanded ex vivo into patients with recent-onset type 1 diabetes (T1D) had an excellent …

New frontiers in the treatment of type 1 diabetes

JT Warshauer, JA Bluestone, MS Anderson - Cell metabolism, 2020 - cell.com
Type 1 diabetes is an autoimmune disease caused by the immune-mediated destruction of
pancreatic β cells that results in lifelong absolute insulin deficiency. For nearly a century …

Low-dose IL-2 therapy in autoimmune and rheumatic diseases

H Graßhoff, S Comdühr, LR Monne, A Müller… - Frontiers in …, 2021 - frontiersin.org
Regulatory T cells (Treg) are crucial for the maintenance of peripheral tolerance and for the
control of ongoing inflammation and autoimmunity. The cytokine interleukin-2 (IL-2) is …

Type 1 diabetes immunotherapy using polyclonal regulatory T cells

JA Bluestone, JH Buckner, M Fitch… - Science translational …, 2015 - science.org
Type 1 diabetes (T1D) is an autoimmune disease that occurs in genetically susceptible
individuals. Regulatory T cells (Tregs) have been shown to be defective in the autoimmune …

Interleukin-2: biology, design and application

N Arenas-Ramirez, J Woytschak, O Boyman - Trends in immunology, 2015 - cell.com
Interleukin-2 (IL-2) exerts crucial functions during immune homeostasis via its effects on
regulatory T (Treg) cells, and the optimizing and fine-tuning of effector lymphocyte …

Engineering IL-2 to give new life to T cell immunotherapy

WW Overwijk, MA Tagliaferri… - Annual review of …, 2021 - annualreviews.org
Interleukin-2 (IL-2) is integral to immune system regulation. Its opposing immunostimulatory
and immunosuppressive actions make it an attractive therapeutic target for cancer and …

Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review

JMK de Filette, JJ Pen, L Decoster… - European journal of …, 2019 - academic.oup.com
Objective To better define the rare adverse event (AE) of diabetes mellitus associated with
immune checkpoint inhibitors (ICIs). Design and methods We report the case of a lung …

Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial

A Hartemann, G Bensimon, CA Payan… - The lancet Diabetes & …, 2013 - thelancet.com
Background An improper balance of regulatory/effector T (T reg/T eff) cells is central to the
development of autoimmune diseases, including type 1 diabetes. We previously showed …